1. Home
  2. NEGG vs IPHA Comparison

NEGG vs IPHA Comparison

Compare NEGG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Newegg Commerce Inc.

NEGG

Newegg Commerce Inc.

N/A

Current Price

$14.56

Market Cap

350.3M

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.92

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEGG
IPHA
Founded
2001
1999
Country
United States
France
Employees
714
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
350.3M
165.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NEGG
IPHA
Price
$14.56
$1.92
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
44.4K
52.7K
Earning Date
04-28-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.50
$1.18
52 Week High
$96.29
$2.71

Technical Indicators

Market Signals
Indicator
NEGG
IPHA
Relative Strength Index (RSI) 36.56 41.28
Support Level $12.52 $1.67
Resistance Level $16.15 $1.95
Average True Range (ATR) 1.10 0.08
MACD -0.41 -0.05
Stochastic Oscillator 2.28 0.00

Price Performance

Historical Comparison
NEGG
IPHA

About NEGG Newegg Commerce Inc.

Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: